NEWS

  • State of the Art Session Addresses Controversies in Antiplatelet Therapy for Patients with CAD

    Antiplatelet drugs should prevent secondary ischemic events and should be safe for long-term use – without incurring an unacceptable increase in bleeding risk. This goal remains elusive, as mortality and morbidity remain high in coronary artery disease (CAD).
    On Wednesday morning, three experts came together during a State of the Art session at the ISTH 2015 …

    READ MORE
  • Topics on Anticoagulant-Associated Bleeding Take Center Stage

    Millions of patients take vitamin K antagonists (VKA) for the treatment and prevention of thromboembolic events, but 1-3% of patients who take them have life-threatening or fatal bleeds. Up to 2% suffer intracranial hemorrhage, which results in death in up to 79% of cases.
    “There are more than 42,000 [hospital] admissions related to serious bleeds with …

    READ MORE
  • Meaningful Genetic Testing for Thrombophilia is Tantalizingly Close

    Multiple strategies for examining genetic determinants of thrombosis are likely to explain clotting events mediated by a complex set of interactions that includes multiple genes and environmental factors, according to David Ginsburg, who delivered Wednesday’s Michael E. Nesheim Plenary Lecture.
    This progress is important, he said, because none of the genes associated with blood clotting disorders …

    READ MORE
  • Earlier Start to Plasma Transfusions for Persistent Postpartum Hemorrhage Does Not Improve Maternal Outcomes

    For women with persistent postpartum hemorrhage, correction of coagulopathy by administering plasma is often an inevitable treatment decision. There are little clinical data, however, on whether an early or a late start for plasma transfusion leads to more positive maternal outcomes.
    Data presented on Wednesday at the ISTH 2015 Congress by Dacia Henriquez of the Department …

    READ MORE
  • Gene Therapy Trial Takes Aim at Hemophilia B

    Researchers may be making some headway in the search for a gene therapy strategy to treat hemophilia B.
    Preliminary findings from an ongoing phase 1-2 trial of an investigational gene therapy treatment to address clotting and immune response in patients with hemophilia B were presented Wednesday at the ISTH 2015 Congress.
    Previous research efforts to use gene …

    READ MORE
  • Member Reflects on Attending 40 Years of ISTH Congresses

    If you’re looking for some insight into the history of ISTH Congresses over the past 40 years, Ian Peake is your guy. He attended his first ISTH Congress in 1975 in Paris as a 31-year-old biochemist working for his mentor, the late Arthur L. Bloom.
    Ian Peake
    “It was daunting,” recalled Peake, who is now emeritus professor …

    READ MORE
  • CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

    Data presented during Late Breaking Session at the 2015 ISTH Congress showed:

    Patients using rVIII-SingleChain prophylactically to prevent bleeding were well controlled when dosed only two or three times weekly
    Prophylactic dosing resulted in low annualized spontaneous bleeding rates and the majority of treated bleeds were controlled with only one dose
    rVIII-SingleChain had improved pharmacokinetic parameters compared with …

    READ MORE
  • Historic Montpellier to serve as backdrop for SSC 2016

    The 62nd Annual Meeting of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis is scheduled to take place in Montpellier, France, May 25-28, 2016.
    In an interview, 2016 SSC Meeting President Jean-Francois Schved said that attendees of SSC 2016 can expect updates from a wide range of topics, including the …

    READ MORE
  • Don’t Miss These Events on Wednesday

    Wednesday features another full day of great events and sessions. See a few highlights below:
    Late-Breaking Abstract Session
    Bleeding disorders, TTP
    8-9:15 | Plenary Room
    Plenary Session 4 – David Ginsburg
    Genetics of thrombosis: from mice to humans
    9:45-10:30 | Plenary Room
    Lunch Symposia
    Click here to see the list of Wednesday’s Lunch Symposia
    12:15-13:45 | Click here for locations
    Posters with Refreshments
    17:15-18:30 | …

    READ MORE
  • Update in the Reversal of Oral Anticoagulants: New Developments and Clinical Strategies

    In the past decade, new oral anticoagulants (NOACs) have transformed the prophylaxis and treatment of thromboembolism. However, few data are available on the reversal of NOACs. Clinicians may face challenges when patients using NOACs present with bleeding complications or prior to urgent interventional procedures.
    Please join us for the symposium Update in the Reversal of Oral …

    READ MORE
  • Official Congress Highlights to Be Available in August

    MD Conference Express and the ISTH are proud to produce the official peer-reviewed Congress highlights from ISTH 2015.
    Sign up to receive the 2015 highlights   
    View the 2013 highlights
    MD Conference Express reports help bridge the gap between live data presentation and academic literature by providing readers with quick coverage and the academic rigor of peer review.  …

    READ MORE
  • Explore the all new ISTH Academy

    In March the International Society on Thrombosis and Haemostasis (ISTH) introduced its new online platform for knowledge and advancement, the ISTH Academy. The Academy offers a highly organized and searchable platform for education, including webinars, webcasts, online courses and much more.
    Monthly ISTH Academy webinars are available on practical thrombosis and hemostasis issues. These webinars feature prominent …

    READ MORE
  • How is the ISTH engaging young professionals? A Q&A with Mandy Lauw

    The ISTH Young Professionals Task Force (YPTF) was organized after the ISTH 2013 Congress in Amsterdam and continues to promote clinical, research and educational activities focused on young investigators. Aligned with the mission of the International Society on Thrombosis and Haemostasis (ISTH), the YPTF aims to increase the awareness of the numerous opportunities to young …

    READ MORE
  • Bayer’s Innovative HJV Tool: Facilitating the Patient-Provider Discussion about Long-Term Joint Health

    For patients with hemophilia, prophylaxis with replacement factor can prevent bleeding episodes, preserve joint function and improve the quality of life, but despite its benefits, there are also barriers to adherence. Conversations between patients and healthcare providers are a critical part in developing targeted and effective treatment plans for patients with hemophilia. However, it’s not …

    READ MORE
  • Reach-the-World program offers important initiatives: A Q&A with Flora Peyvandi

    The ISTH Reach-the-World program offers fellowships to members in developing countries and helps to arrange education courses in countries around the world. The ISTH has awarded 21 fellowships to individuals from 12 different countries and sponsored 60 education courses in 35 different countries. To learn more, we interviewed Flora Peyvandi, a Reach-the-World mentor and member …

    READ MORE

PLENARIES

  • Meaningful Genetic Testing for Thrombophilia is Tantalizingly Close

    Multiple strategies for examining genetic determinants of thrombosis are likely to explain clotting events mediated by a complex set of interactions that includes multiple genes and environmental factors, according to David Ginsburg, who delivered Wednesday’s Michael E. Nesheim Plenary Lecture.
    This progress is important, he said, because none of the genes associated with blood clotting disorders …

    READ MORE

SOCIAL

STATE-OF-THE-ART

  • State of the Art Session Addresses Controversies in Antiplatelet Therapy for Patients with CAD

    Antiplatelet drugs should prevent secondary ischemic events and should be safe for long-term use – without incurring an unacceptable increase in bleeding risk. This goal remains elusive, as mortality and morbidity remain high in coronary artery disease (CAD).
    On Wednesday morning, three experts came together during a State of the Art session at the ISTH 2015 …

    READ MORE
  • Topics on Anticoagulant-Associated Bleeding Take Center Stage

    Millions of patients take vitamin K antagonists (VKA) for the treatment and prevention of thromboembolic events, but 1-3% of patients who take them have life-threatening or fatal bleeds. Up to 2% suffer intracranial hemorrhage, which results in death in up to 79% of cases.
    “There are more than 42,000 [hospital] admissions related to serious bleeds with …

    READ MORE

AWARDS